GALNT9-AS1: A Potential Drug Target and Biomarker (G100130238)

Target Name: GALNT9-AS1

NCBI ID: G100130238

GALNT9-AS1

Other Name(s): GALNT9 antisense RNA 1

GALNT9-AS1: A Potential Drug Target and Biomarker

GALNT9-AS1 is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The gene is located on chromosome 16 and encodes for the Galectin-9 (Gal9) protein, which is a type of carbohydrate-binding protein that is expressed in various tissues and cells throughout the body.

Gal9 is known for its unique structure and function. It consists of a single domain that contains a carbohydrate-binding domain, a catalytic domain, and a cytoplasmic tail. The carbohydrate-binding domain is the most well-studied part of the protein and is responsible for its ability to interact with carbohydrates. This interaction is critical for the function of the protein, as carbohydrates are found in almost all cells and play a vital role in various cellular processes, including cell signaling, signaling pathways, and tissue structure.

GALNT9-AS1 has been shown to be involved in many different cellular processes, including cell signaling, angiogenesis, and neurodegenerative diseases. For example, studies have shown that Gal9 can interact with various proteins and carbohydrates, including cadherins, N-cadherins, and ganglioside receptors. This interaction suggests that Gal9 may be involved in cell signaling pathways, where Gal9 can play a role in regulating the movement and behavior of cells.

In addition to its role in cell signaling, Gal9 has also been shown to be involved in the development and progression of various diseases, including cancer and neurodegenerative disorders. For example, studies have shown that Gal9 is overexpressed in various types of cancer, including breast, ovarian, and prostate cancer. This overexpression is thought to contribute to the development and progression of these diseases. Additionally, Gal9 has also been shown to be involved in the development of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease.

GALNT9-AS1 has also been shown to be a potential biomarker for these diseases. For example, studies have shown that Gal9 can be used as a diagnostic marker for cancer, by detecting the expression of the gene in tissue samples from cancer patients. Additionally, the levels of Gal9 have also been shown to be elevated in the blood and urine of patients with neurodegenerative disorders, making it a potential biomarker for these diseases.

In conclusion, GALNT9-AS1 is a gene that has the potential to be a drug target and biomarker for various diseases. Its unique structure and function, as well as its involvement in cell signaling pathways and the development of various diseases, make it an attractive target for drug developers. Further research is needed to fully understand the role of Gal9 in these diseases and to develop effective treatments.

Protein Name: GALNT9 Antisense RNA 1

The "GALNT9-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GALNT9-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets